Spero Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Spero Therapeutics has a total shareholder equity of $65.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $135.2M and $69.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$76.29m |
| Equity | US$65.51m |
| Total liabilities | US$69.65m |
| Total assets | US$135.16m |
Recent financial health updates
We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
Apr 05
We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate
Jul 04We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely
Mar 17Recent updates
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding
Nov 02Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
Jul 15Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Apr 23Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 12Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jan 02Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
May 18Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Apr 17Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Apr 13We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
Apr 05Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
Oct 03Spero Therapeutics appoints Kamal Hamed MD CMO
Sep 15Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate
Sep 06Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M
Aug 10We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate
Jul 04We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely
Mar 17Financial Position Analysis
Short Term Liabilities: SPRO's short term assets ($131.6M) exceed its short term liabilities ($49.1M).
Long Term Liabilities: SPRO's short term assets ($131.6M) exceed its long term liabilities ($20.6M).
Debt to Equity History and Analysis
Debt Level: SPRO is debt free.
Reducing Debt: SPRO had no debt 5 years ago.
Debt Coverage: SPRO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: SPRO has no debt, therefore coverage of interest payments is not a concern.